[Antioxidant power and cellular damage in prostate cancer]. / Poder antioxidante y daño celular en el carcinoma de próstata.

OBJECTIVES: To determine and compare the antioxidant power, cellular damage by lipidic peroxidation, and membrane damage in normal patients and patients with prostate cancer, so determining the antitumoral capacity. METHODS: The study population included 19 patients with elevated total PSA, greater than 4 ng/ml, with a minimum of 10 ultrasound guided transrectal biopsies, and 10 normal subjects as control group. In all cases, medical history, rectal digital examination, PSA determination and routine analyses were performed in addition to spectrophotometric tests to measure the antioxidant power. Membrane damage was measured by determination of malonyldialdehyde (MDA) and cellular damage by glutathione peroxidase. RESULTS: From a total of 19 cases: 6 (31.5%) presented prostate cancer (4 Gleason 7; 1 Gleason 6 and 1 Gleason 8); 8 presented histological benign prostatic hyperplasia with a component of chronic prostatitis; 3 patients prostatic hyperplasia and glandular atrophy; and 2 cases isolated benign prostatic hyperplasia. All 10 control patients presented values within normal range in all determinations, whereas study patients showed antioxidant power < 1.3 mmol/l in 13 cases; higher than 1.77 mmol/l in 4 and normal values in 2. MDA was elevated in 15 patients and normal in 4, all of them without histological chronic prostatitis. Four of the patients with prostate cancer presented a diminished antioxidant power below 0.90, with a relationship with glandular architecture, because those with Gleason 8 and 7 did not exceed 0.58 mmol/l. Two patients with prostate cancer with a lower Gleason score presented normal minimal values. CONCLUSIONS: Patients with prostate cancer or reactive processes, such as chronic prostatitis or atrophic prostatitis, present a decreased antioxidant power and an increase of lipidic peroxidation.

Poder antioxidante y daño celular en el carcinomá de próstata / Antioxidant power and cellular damage in prostate cancer

Objetivos: Determinar y comparar el poder antioxidante, el daño celular por peroxidación lipídica y el daño de membrana en pacientes normales y en aquellos con carcinoma de próstata y así, determinar la capacidad antitumoral. Método: La población estuvo constituida por 19 pacientes con PSA total elevado, mayor de 4ng/ml con un mínimo de 10 biopsias transrectales ecodirigidas y 10 sujetos normales como grupo control. En todos los casos se efectuó historia clínica, tacto rectal, examen de PSA y analítica de rutina; además de técnicas espectrofotométricas para medir poder antioxidante. El daño de membrana se midió a través de la malonildialdehido (MDA) y el daño celular mediante la glutation pexoxidasa. Resultados: Del total de 19 casos: 6 (31,5%) presentaron carcinoma de próstata (4 con Gleason 7; 1 con Gleason 6 y 1 con Gleason 8); 8 presentaron histopatológicamente hiperplasia benigna de próstata con componente de prostatitis crónica ; 3 pacientes con hiperplasia prostática y atrofia glandular; y 2 casos con hiperplasia benigna de próstata aislada. Los 10 sujetos considerados controles presentaron un rango de normalidad en las todas las determinaciones. Mientras que en los pacientes estudiados, el poder antioxidante fue menor a 1,30 mmol/L en 13 casos; superó 1,77 mmol/L en 4 sujetos y 2 persistieron en valores normales. La MDA se encontró aumentada en 15 pacientes y 4 fueron normales siendo aquellos que no tenían prostatitis crónica en su histología. Cuatro de los pacientes con carcinoma de próstata presentaron 4 un poder antioxidantes disminuido menor a 0.90, estando en relación a la arquitectura glandular, ya que los de Gleason 8 y 7 no superaron 0,58 mmol/l. Dos pacientes con carcinoma de próstata de Gleason más bajo presentaron valores mínimos normales. Conclusiones: Los pacientes con carcinoma de próstata o procesos reactivos, como la prostatitis crónica y la prostatitis atrófica, presentan una disminución del poder antioxidante y un aumento de la peroxidación lipídica (AU)

Objectives: To determine and compare the antioxidant power, cellular damage by lipidic peroxidation, and membrane damage in normal patients and patients with prostate cancer, so determining the antitumoral capacity. Methods: The study population included 19 patients with elevated total PSA, greater than 4 ng /ml, with a minimum of 10 ultrasound guided transrectal biopsies, and 10 normal subjects as control group. In all cases, medical history, rectal digital examination, PSA determination and routine analyses were performed in addition to spectrophotometric tests to measure the antioxidant power. Membrane damage was measured by detemination of malonyldialdehyde (MDA) and cellular damage by glutathione peroxidase. Results: From a total of 19 cases: 6 (31.5%) presented prostate cancer (4 Gleason 7; 1 Gleason 6 and 1 Gleason 8); 8 presented histological benign prostatic hyperplasia with a component of chronic prostatitis; 3 patients prostatic hyperplasia and glandular atrophy; and 2 cases isolated benign prostatic hyperplasia. All 10 control patients presented values within normal range in all determinations, whereas study patients showed antioxidant power < 1.3 mmol/l in 13 cases; higher than 1.77 mmol/l in 4 and normal values in 2. MDA was elevated in 15 patients and normal in 4, all of them without histological chronic prostatitis. Four of the patients with prostate cancer presented a diminished antioxidant power below 0.90, with a relationship with glandular architecture, because those with Gleason 8 and 7 did not exceed 0.58 mmol/l. Two patients with prostate cancer with a lower Gleason score presented normal minimal values. Conclusions: Patients with prostate cancer or reactive processes, such as chronic prostatitis or atrophic prostatitis, present a decreased antioxidant power and an increase of lipidic peroxidation (AU)